Core Viewpoint - The integration of Adaptive Biotechnologies' clonoSEQ test for measurable residual disease (MRD) assessment into Flatiron Health's OncoEMR platform enhances access to MRD testing for clinicians, improving treatment decision-making for blood cancer patients [1][2][3][4]. Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [8][9]. - Flatiron Health is a healthtech company dedicated to advancing point-of-care solutions in oncology, utilizing data to improve cancer care [10]. Product Integration - The clonoSEQ test will be integrated into OncoEMR, allowing over 4,500 clinicians across 1,000 community-based cancer care locations in the U.S. to order and review MRD testing results directly within the EMR [2][4]. - This integration aims to streamline access to MRD data, enabling community clinicians to make more informed treatment decisions for blood cancer patients [3][4]. Clinical Significance - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting and tracking MRD in multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, among other lymphoid cancers [5][6]. - The test can detect one cancer cell in one million healthy cells, providing precise monitoring of MRD over time, which is crucial for predicting patient outcomes and informing treatment strategies [6][7]. Market Impact - The integration of clonoSEQ into OncoEMR is expected to enhance the efficiency of testing workflows and provide real-time insights into patients' disease status, ultimately improving patient care in community oncology settings [2][4][11].